R&D News | pharmaphorum

News

enGene is hoping to file its gene for a form of bladder cancer before the end of 2026, based on phase 2 data revealing a 62% complete response rate.

News

Daiichi Sankyo has started clinical testing of a STING agonist for cancer, a class that has been hit by safety issues and discontinued programmes.

News

MSD closes on filing for enlicitide, a PCSK9 inhibitor that could offer the efficacy of injectables with the ease of a once-daily pill.

News

Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for multiple sclerosis after clearing two phase 3 trials.

News

AstraZeneca's data reveal for resistant hypertension treatment baxdrostat suggests its optimism about big sales for the drug could be justified.

News

People with hypertension were twice as likely to take medicine regularly when offered cash rewards, but that didn't improve their blood pressure.